WO2012140013A2 - Nouvelle utilisation de compositions pour le traitement d'états inflammatoires de la peau, d'états écailleux du cuir chevelu et du remodelage de collagène - Google Patents

Nouvelle utilisation de compositions pour le traitement d'états inflammatoires de la peau, d'états écailleux du cuir chevelu et du remodelage de collagène Download PDF

Info

Publication number
WO2012140013A2
WO2012140013A2 PCT/EP2012/056451 EP2012056451W WO2012140013A2 WO 2012140013 A2 WO2012140013 A2 WO 2012140013A2 EP 2012056451 W EP2012056451 W EP 2012056451W WO 2012140013 A2 WO2012140013 A2 WO 2012140013A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
extract
species
conditions
scaly
Prior art date
Application number
PCT/EP2012/056451
Other languages
English (en)
Other versions
WO2012140013A3 (fr
Inventor
Saad Harti
Original Assignee
Legacy Healthcare Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legacy Healthcare Holding Ltd filed Critical Legacy Healthcare Holding Ltd
Publication of WO2012140013A2 publication Critical patent/WO2012140013A2/fr
Publication of WO2012140013A3 publication Critical patent/WO2012140013A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Definitions

  • the invention concerns a new use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling.
  • compositions containing as active ingredient an extract of Allium species, an extract of Citrus species and
  • the common form of hair loss in both men and women is mainly due to the predominance binding of the male sex hormone testosterone and 5alpha-dihydrotestosterone / DHT (which are also present in women in trace amounts) to the androgen receptor of the matrix cells in the dermal papilla. This leads to decreased duration of the anagen hair as well as inhibition of hair follicle activities along with an early induction of the catagen and prolongation of telogen phase.
  • the hair follicle Under its physiological circumstances (absence of inflammation), the hair follicle is surrounded by healthy connective tissue and dermal papilla.
  • an increase of DHT hormone will cause premature apoptosis of cells in both dermal papilla and extra matrix connective tissue.
  • Abnormal cell apoptosis results in involution of the hair follicle, hair miniaturization, loss of the connective tissue integrity, lack of collagen and continued hair shedding. This process is accompanied and enhanced by the inflammatory conditions in the scalp that will cause further hair loss.
  • testosterone/DHT is at the core of the balding process
  • an increased sensitivity to testosterone is also the maj or cause for Acne, a disease of the hair follicles of the face, chest, back, shoulders and upper arms, which affects both males and females especially during puberty.
  • Such an oversensitivity to testosterone causes the sebaceous glands in the pilosebaceous unit (consisting of a hair follicle, sebaceous gland, and a hair) to secrete sebum excessively and brings sebaceous glands and hair follicles into chronic inflammatory disease conditions.
  • skin cells divide so rapidly as to block the opening of hair follicles in the skin. Behind this blockage, sebum builds up and forms blackheads and whiteheads.
  • Propionibacteria acnes Due to the pH changes that provide the bacteria (Propionibacteria acnes) with favorable micro- environment, the bacteria overgrow rapidly and become trapped in the hair follicles, producing a deeper infection in the form of pustules and nodules. Propionibacteria acnes in blocked pores will further trigger inflammatory response by the immune system in order to defend the body against infection. The sustained inflammation will result pain, heat, swelling and redness, destroying healthy tissue and cause more damage and leave scattered lesions / acne scars. Acne affects people of all races and skin types and occurs mostly in teenagers but also in adults in their twenties through to their forties.
  • acne There are several different types of acne, which can be categorized into six different forms: Acne Vulgaris, Acne conglobata, Acne fulminans, Gram-negative folliculitis, Acne Rosacea and Pyoderma faciale.
  • Acne Vulgaris it is the most common form of acne, starting from puberty to twenties, thirties or beyond. Although that may emerge all over the body, most commonly it appears on the face, neck, chest, and back, forming different types of lesions such as Papules (red, inflamed bumps called papules), Whiteheads (resulting from a pore that is blocked
  • Blackheads due to partially blocked pore
  • Pustules due to partially blocked pore
  • Pustules due to an inflamed red circle with a white or yellow center
  • Nodules hard and large bumps under the skin that may last for months.
  • Acne Conglobata a very severe form of acne vulgaris commonly occurring in males between 18 and 30 years old. It may be found on the face, back, chest, back, upper arms, and thighs, presenting blackheads and interconnected large lesions which can cause permanent damage to the skin.
  • Acne Fulminans in fact, it is an abrupt emergence of acne conglobata, which often becomes ulcerated and severely scarred. In some people, acne fulminans may cause aching joints and a fever.
  • Gram-Negative Folliculitis characterized by cysts and pustules due to bacterial infection. Little knowledge is available concerning this condition.
  • Acne Rosacea similar in appearance to vulgaris, but found as a red rash (coming with or without pimples, bumps and blemishes) restricted to the nose, cheeks, chin, and forehead.
  • Pyoderma Faciale a severe acne form (nodules) only found on the face of females. It may be painful, uncomfortable and severely scarring if untreated.
  • the root cause and issues of acne are related to hormones, inflammatory conditions, infection, hyper-pigmentation and collagen modelling (acne scars).
  • the efficacious product for acne management should address such causes and issues. This would mean that the actions of an ideal treatment (like this invention) should have the following characteristics: reducing androgen-effect, dampening inflammation, disabling bacterial infection, remodelling collagen and reducing skin hyper pigmentation / acne scars.
  • Inflammation can be induced by apoptotic cells that release inflammatory cytokines such as Fas ligand (Brown SB et al. J Immunol, 1999 162:2110-9; Stuart LM et al. J Immunol 2003 171 :2610-5).
  • cytokines such as Fas ligand
  • Bcl-2 the abnormal cell apoptosis process can be inhibited and consequently the inflammation be attenuated.
  • JL Niu et al. previously showed that Bcl-2 expression attenuated inflammation in the context of monocyte chemoattractant protein- 1(MCP-1)- induced cardiomyopathy (Cardiovascular Research 71 , 2006 1 9 - 148).
  • Epidermal Langerhans cells are distinct tissue dendritic cells (antigen-presenting immune cells) located in the skin epidermis and mucosa. They are thought to play a key role to initiate adaptive immune responses. Daniel H. Kaplan et al. (Immunity, Dec. 2005 Vol. 23, 611-620,) further revealed an unappreciated function of Langerhans cells to dampen the skin's reaction to inflammation and infection. Thus, Langerhans cells may play an important role in preventing excessive immune and inflammatory responses in the skin.
  • Langerhans cells may improve inflammatory skin conditions and autoimmune diseases such as lupus (especially skin lupus), psoriasis, skin transplantation, keratosis, contact hypersensitivity (CHS), sunburn, dandruff, scar treatment and wound healing, as well as dermatitis or eczema, of which at least seven types have been identified: Contact eczema, Allergic contact eczema, Seborrheic eczema, Nummular eczema, Neurodermatitis, Stasis dermatitis and Dyshidrotic eczema.
  • lupus especially skin lupus
  • psoriasis skin transplantation
  • keratosis contact hypersensitivity (CHS)
  • CHS contact hypersensitivity
  • sunburn sunburn
  • dandruff scar treatment and wound healing
  • dermatitis or eczema of which at least seven types have been identified: Contact eczema
  • psoriasis is a common autoimmune inflammatory skin disorder affecting about 2% of the population. It occurs when the immune system mistakes the skin cells as a pathogen, sends out wrong signals so that the psoriasis plaques exhibits abnormal proliferation and differentiation of epidermal keratinocytes. Such skin inflammation process leads to five types of psoriasis: plaque, guttate, inverse, pustular and erythrodermic psoriasis. The most common is chronic plaque psoriasis, consisting of red, heavily scaled, well-demarcated plaques on elbows, knees, scalp, lower back and any other skin surface.
  • an ideal agent (like this invention) should have the properties to normalize the immune capacity by further mobilizing epidermis Langerhans cells in the aim to attenuate the irregular inflammatory process in psoriasis.
  • Wound healing is a complex and dynamic process of restoring cellular structures and tissue layers, which can be divided into 3 distinct phases: the inflammatory phase, the proliferative phase and the remodeling phase. Coordinated series of biological / biochemical processes for repairing the damaged tissues include chemotaxis, apoptosis, phagocytosis, angiogenesis (producing new capillaries), production of new glycosaminoglycans, proteoglycans, neocollagenesis, collagen degradation and collagen remodeling.
  • apoptosis has been previously described in many physiological processes as exampled above in case of hair loss
  • recent research work has shown that apoptosis / anti- apoptosis mechanism is also actively involved in skin wound healing or scar formation.
  • a better understanding of the regulation of apoptosis e.g. for removal of inflammatory cells or fibroblasts during dermal reconstruction / skin graft
  • anti-apoptosis e.g. for promotion of fibroblasts, epithelial cells growth in the proliferative phase
  • the healing process can go wrong and bring about either insufficient healing (e.g. atrophic scar formation) or an exuberance of fibroblastic proliferation (e.g. hypertrophic scar). Further exuberance can result in keloid formation, where the body continues to produce tough, fibrous collagen after a wound has healed.
  • Persistent inflammation, disorders in proliferation (or apoptosis), Angiogenesis and collagen modeling may end in non-healing wounds or pathologic responses leading to fibrosis or chronic ulcers.
  • limiting irregular inflammation and keeping ordered processes of cell proliferation, Angiogenesis and collagen deposition / remodeling will be paramount to an effective wound healing such as in epidermis regeneration, scar reduction and skin implants.
  • a natural product for scar or wound management should be able to help the human body regulate healing processes in order to avoid
  • the skin consists of the epidermis (superficial layer, an outermost layer of the skin) and the dermis (a deeper vascular connective tissue).
  • the epidermis is mainly made up of keratinocytes and stratified with squamous epithelium. Older cells migrate up to the surface of the skin, wear off daily and constantly replaced by newly produced cells.
  • the dermis consists of dense connective tissue with blood vessels, lymphatic glands, nerve receptors and hair follicles. Elastic fibers in the dermis give the skin its elasticity nature. These elastic fibers degenerate because of the age-related process (aging) and inflammation. Furthermore, the boundary between dermis and epidermis becomes undulating and dermal papilla projecting into the epidermis, which consequently make the skin wrinkled.
  • Dermal papilla plays pivotal roles not only in hair formation, growth and cycling, but also in strengthening the dermal and epidermal layers by forming ridges in-between. Meanwhile, it supports the epidermis and facilitates the exchange of oxygen, nutrients, and waste products between these two layers. With age, because of cell apoptosis (either naturally programmed or premature), the papillae tend to flatten. This is another factor that contributes to the wrinkled skin.
  • intervention by natural anti-apoptotic agent may reduce fine wrinkles in the skin.
  • Such an agent will decelerate or prevent the skin cells, especially those in the dermal papillae, from premature cell apoptosis due to insults from surrounding environment.
  • Stretch marks also called Striae Distensae
  • red and white stretch marks There exist two types: red and white stretch marks. They appear in a range of pigmentations being red, pink, purple, brown, reddish or dark brown. Up to 90% of pregnant women, 70% of pubescent girls and 40% of pubescent boys develop stretch marks. For this reason, they are believed to be hormone-related, such as during pregnancy, puberty, and advancing obesity, where the glucocorticoid levels get much higher. It could also be related to rapid weight gain and use of certain medications (e.g. adrenal hormones), exampled by the cases in serious weight-lifters and the majority of obese sufferers.
  • certain medications e.g. adrenal hormones
  • compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling and more particularly of all skin disorders related to inflammation, apoptosis, angiogenesis and collagen / collagen remodeling, fine lines & wrinkles, chronic wounds, acute wounds, incisional wounds, burn wounds, hypertrophic scars, keloid, skin implant, skin graft scars, acne, acne scars, psoriasis, rashes, cracked and dry skin, seborrheic and actinic keratosis, lupus, especially skin lupus / acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, chronic cutaneous lupus erythematosus) and all types of dermatitis or eczema, contact hypersensitivity (CHS), hyper-pigmentation / melasma, skin ulcers, post-surgical scars, dandruff
  • compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling those which are of more particular interest are the uses in which the preferred topical composition contains an aqueous-alcoholic extract of Allium species, an aqueous-alcoholic extract of Citrus species, an aqueous alcoholic extract (atomised or not) of Paullinia species and an aqueous-alcoholic extract (atomised or not) of Theobroma species.
  • compositions are containing from 65% to 93% of an aqueous-alcoholic extract of Allium species, from 5% to 33% of an aqueous-alcoholic extract of Citrus species, from 0.25% to 2.5% of an aqueous-alcoholic extract (atomised or not) of Paullinia species and from 0.25% to 2.5% of an aqueous-alcoholic extract (atomised or not) of Theobroma species and especially those containing from 65% to 93% of an aqueous-alcoholic extract of Allium cepa, from 5% to 33% of an aqueous-alcoholic extract of Citrus lemon, from 0.25% to 2.5% of an aqueous-alcoholic extract (atomised or not) of Paullinia species and from 0.25% to 2.5% of an aqueous-alcoholic extract (atomised or not) of Theobroma species.
  • extract of Allium species is containing from 65% to 93% of an aqueous-alcoholic extract of Allium species, from 5% to 33% of an aqueous-alcoholic extract of Cit
  • extract of Citrus species or aqueous-alcoholic extract of Citrus species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Citrus (family Rutaceae) and especially Citrus lemon.
  • extract (atomised or not) of Paullinia species or aqueous-alcoholic extract (atomised or not) of Paullinia species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Paullinia (family Sapindaceae) and especially Paullinia cupana.
  • extract atomised or not
  • aqueous-alcoholic extract atomised or not
  • compositions used according to the invention are those containing approximately 87% of an aqueous-alcoholic extract of Allium cepa, approximately 12% of an aqueous-alcoholic extract of Citrus lemon, approximately 0.5% of an aqueous-alcoholic extract (atomised or not) of Paullinia cupana and approximately 0.5% of an aqueous- alcoholic extract (atomised or not) of Theobroma cacao.
  • the invention concerns also a method for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling, and more particularly of all skin disorders related to inflammation, apoptosis, angiogenesis and collagen / collagen remodeling, fine lines & wrinkles, chronic wounds, acute wounds, incisional wounds, burn wounds, hypertrophic scars, keloid, skin implant, skin graft scars, acne, acne scars, psoriasis, rashes, cracked and dry skin, seborrheic and actinic keratosis, lupus, especially skin lupus / acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, chronic cutaneous lupus erythematosus) and all types of dermatitis or eczema, contact hypersensitivity (CHS), hyper-pigmentation / melasma, skin ulcers, post-surgical scars, dandruff, acne, wound
  • compositions are prepared as indicated in patent application.
  • compositions and /or the cosmetic compositions are prepared by conventional methods, in which pharmaceutically inert, organic or inorganic excipients are added to the compositions obtained according to the invention.
  • the composition is administered daily during a period of several months with a composition containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species.
  • compositions obtained according to the invention When using the compositions obtained according to the invention, doses may vary within relatively wide limits and must be set according to the person being treated and the condition concerned.
  • Pharmaceutical compositions and /or cosmetic compositions normally contain from 0.2 to 500 mg, preferably from 1 to 200 mg, of active ingredients as defined above, in the form of dry extract.
  • compositions As a drug
  • composition A 40 g per 100 ml
  • composition A 21 g per 100 ml
  • Treatment Application 1 to 2 times daily massage.
  • Active ingredient Composition A 10 %>
  • Treatment 1 shampoo every day.
  • Active ingredient Composition A 20 %
  • Treatment 1 shampoo every day.
  • Treatment Application 1 to 2 times daily massage.
  • Treatment Application 1 to 2 times daily massage.
  • composition A (hereafter composition A).
  • This lotion has been prepared as indicated in example 1 of patent application WO 2008/113912.
  • Composition A which is a mixture of four natural ingredients has been reported to beneficially affect the Anagen/Telogen ratio in men with androgenetic alopecia and women suffering from Female Pattern Hair Loss. In addition, people using the product occasionally accelerated re-growth of hair.
  • composition A is capable of affecting positively the hair cycle after the shedding (telogen) process, in order to provoke a quicker restart next hair growth (anagen) phase, as such shortening the resting phase.
  • telogen shedding
  • anagen hair growth
  • composition A had significant beneficial effects on hair growth and hair cycle.
  • biochemical observations however have suggested other substantial features that point towards additional uses of the natural mixture Observation 1: Collagen remodeling
  • composition A twice a day for four months.
  • Scalp biopsies were taken at start and at Day 120. Histological sections at day 0 showed small and thin collagen fibers with disorganized appearance. Histological sections of the scalp biopsies at day 120 showed a higher density of collagen fibers which were also better organized and thicker in appearance.
  • composition A The animal data obtained in mice (applying non-formulated composition A), corroborated by the human data observed on scalp biopsies, confirm a profound effect of composition A on the formation of collagen in the dermis.
  • the outcome of the histological examinations of the human biopsies indicates a potent effect of Composition A on a number of histological markers associated with inflammation, apoptosis and angiogenesis.
  • the marked changes of those parameters support the beneficial activities in anti-inflammation, regulation of apoptosis, angiogenesis and collagen remodeling. It is known that often AGA is associated with increased inflammatory reactions around the hair follicle, accelerating as such the exogen of the hair.
  • composition A will beneficially affect a variety of inflammatory conditions in scalp and skin, as there are: dandruff, acne, wound healing, rosacea, management of sun burn, psoriasis, seborrheic dermatitis, atopic dermatitis and all types of eczema.
  • composition A will result in beneficial effects in a variety of skin disorders related to inflammation, apoptosis,
  • angiogenesis and collagen / collagen remodeling are: fine lines & wrinkles, , chronic wounds, acute wounds, incisional wounds, burn wounds, hypertrophic scars, keloid, skin implant, skin graft scars, acne, acne scars, psoriasis, rashes, cracked and dry skin, seborrheic and actinic keratosis, lupus (especially skin lupus / acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, Chronic cutaneous lupus
  • erythematosus and all types of dermatitis or eczema, Contact hypersensitivity (CHS), Hyper- pigmentation / Melasma, skin ulcers, post-surgical scars, scaly hair and scaly skin that can also be found in Ichthyosis.
  • CHS Contact hypersensitivity
  • Hyper- pigmentation / Melasma skin ulcers
  • post-surgical scars scaly hair and scaly skin that can also be found in Ichthyosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention porte sur une nouvelle utilisation de compositions pour le traitement d'états inflammatoires de la peau, d'états écailleux du cuir chevelu et du remodelage de collagène, et, plus particulièrement, de tous les troubles de la peau relatifs à l'inflammation, comprenant l'administration par voie topique d'une composition contenant, en tant que principe actif, un extrait d'une espèce du genre Allium, un extrait d'une espèce du genre Citrus, un extrait d'une espèce du genre Paullinia et un extrait d'une espèce du genre Theobroma. L'invention porte également sur un procédé pour le traitement des maladies mentionnées ci-dessus avec les mélanges mentionnés ci-dessus lorsqu'ils sont formulés sous la forme de n'importe quelle formulation topique destinée à être utilisée sur les cheveux, le cuir chevelu et la peau, comprenant, mais sans y être limitée, des crèmes, des onguents, des gels, des teintures, des mousses, des liquides, des solutions, des suspensions, des poudres, des pulvérisations.
PCT/EP2012/056451 2011-04-11 2012-04-10 Nouvelle utilisation de compositions pour le traitement d'états inflammatoires de la peau, d'états écailleux du cuir chevelu et du remodelage de collagène WO2012140013A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473954P 2011-04-11 2011-04-11
US61/473,954 2011-04-11

Publications (2)

Publication Number Publication Date
WO2012140013A2 true WO2012140013A2 (fr) 2012-10-18
WO2012140013A3 WO2012140013A3 (fr) 2013-04-04

Family

ID=45953139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/056451 WO2012140013A2 (fr) 2011-04-11 2012-04-10 Nouvelle utilisation de compositions pour le traitement d'états inflammatoires de la peau, d'états écailleux du cuir chevelu et du remodelage de collagène

Country Status (1)

Country Link
WO (1) WO2012140013A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862598A1 (fr) * 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Utilisation d'une composition pour la pigmentation des cheveux et des poils
CN107438428A (zh) * 2015-02-19 2017-12-05 Elc 管理有限责任公司 新型皮肤重塑策略
US10357531B2 (en) 2013-11-08 2019-07-23 Legacy Healthcare Ltd. Method for the management of cancer and cancer treatment-related comorbidities
WO2021224455A1 (fr) * 2020-05-07 2021-11-11 Legacy Healthcare (Switzerland) Sa Composition pour renforcement du système immunitaire chez l'homme et l'animal en vue de l'acquisition d'une immunité globale
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113912A2 (fr) 2007-02-13 2008-09-25 Legacy Healthcare Holding Ltd. Nouvelles compositions cosmetiques et/ ou pharmaceutiques et leurs applications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2511714B2 (ja) * 1989-12-05 1996-07-03 一丸ファルコス株式会社 植物由来抽出成分からなるフケ菌発育阻害剤を含有する皮膚・頭皮・頭髪用化粧料
JPH04342517A (ja) * 1990-07-20 1992-11-30 Yutaka Miyauchi ５α−リダクターゼ阻害剤
DE102004011968A1 (de) * 2004-03-10 2005-09-29 Henkel Kgaa Präbiotisch wirksame Pflanzenextrakte
DE202004012348U1 (de) * 2004-08-03 2004-10-07 Jabal Amman, Suhbi Hasan Mohammes Zubereitung zur Pflege der Haut bei Psoriasis oder Ekzem
JP4804805B2 (ja) * 2005-06-10 2011-11-02 横関油脂工業株式会社 細胞賦活剤、紫外線障害緩和剤及びメラニン産生抑制剤
US20070280898A1 (en) * 2006-06-06 2007-12-06 P & H Enterprises Of Marco Inc. Dermatological compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113912A2 (fr) 2007-02-13 2008-09-25 Legacy Healthcare Holding Ltd. Nouvelles compositions cosmetiques et/ ou pharmaceutiques et leurs applications

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROWN SB ET AL., J IMMUNOL, vol. 162, 1999, pages 2110 - 9
CARDIOVASCULAR RESEARCH, vol. 71, 2006, pages 139 - 148
DANIEL H. KAPLAN ET AL., IMMUNITY, vol. 23, December 2005 (2005-12-01), pages 611 - 620
KANE ET AL., WOUND REP REG, vol. 8, 2000, pages 45 - 58
MARIE CUMBERBATCH ET AL., JEM, vol. 203, no. 4, April 2006 (2006-04-01), pages 953 - 960
STUART LM ET AL., J IMMUNOL, vol. 171, 2003, pages 2610 - 5

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862598A1 (fr) * 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Utilisation d'une composition pour la pigmentation des cheveux et des poils
WO2015055739A1 (fr) * 2013-10-16 2015-04-23 Legacy Healthcare Ltd Utilisation d'une composition pour la pigmentation des cheveux et des poils
CN105813694A (zh) * 2013-10-16 2016-07-27 传统医疗保健有限公司 用于毛发和体毛的色素沉着的组合物的用途
US11219592B2 (en) 2013-10-16 2022-01-11 Legacy Healthcare (Switzerland) Sa Use of a composition for the pigmentation of hair and hairs
US10357531B2 (en) 2013-11-08 2019-07-23 Legacy Healthcare Ltd. Method for the management of cancer and cancer treatment-related comorbidities
CN107438428A (zh) * 2015-02-19 2017-12-05 Elc 管理有限责任公司 新型皮肤重塑策略
JP2018508778A (ja) * 2015-02-19 2018-03-29 イーエルシー マネージメント エルエルシー 新規皮膚リモデリング戦略
WO2021224455A1 (fr) * 2020-05-07 2021-11-11 Legacy Healthcare (Switzerland) Sa Composition pour renforcement du système immunitaire chez l'homme et l'animal en vue de l'acquisition d'une immunité globale
FR3109881A1 (fr) * 2020-05-07 2021-11-12 Legacy Healthcare (Switzerland) Sa Procede pour ameliorer le systeme immun pour acquerir la pan-immunite
CN115666525A (zh) * 2020-05-07 2023-01-31 传世医疗(瑞士)有限公司 用于增强人和动物免疫系统以获得多种免疫的组合物
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Also Published As

Publication number Publication date
WO2012140013A3 (fr) 2013-04-04

Similar Documents

Publication Publication Date Title
KR101420599B1 (ko) 항여드름제를 함유하는 조성물 및 이의 용도
JP5570992B2 (ja) 皮膚病又は皮膚病変の治療方法及び組成物
CN104667335A (zh) 皮肤屏障功能或痔的重组人源胶原蛋白产品及制备方法
EA032439B1 (ru) Композиции и способы для лечения поверхностных ран
US9622950B2 (en) Compositions for use in treatment of dermatological diseases and conditions
WO2012140013A2 (fr) Nouvelle utilisation de compositions pour le traitement d'états inflammatoires de la peau, d'états écailleux du cuir chevelu et du remodelage de collagène
CN113171327A (zh) 控油祛痘组合物及其应用
US20060222689A1 (en) Skin care compositions and methods
KR102141574B1 (ko) 두피케어 화장료 조성물 및 그 제조방법
JP2004059482A (ja) 組織再生促進剤
US20170281690A1 (en) Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis
US20200030398A1 (en) Skin care composition
CN112220794A (zh) 柠檬苦酸的防脱发和生发用途
WO2020232181A1 (fr) Compositions comprenant des extraits de plantes et des huiles et méthodes de traitement associées et leur préparation
CN108938514B (zh) 一种清肤祛痘液及其制备方法
KR20190092822A (ko) 압타민 c를 유효성분으로 포함하는 피부질환 개선 및 치료용 조성물
US20060115503A1 (en) Composition, system and method for treatment of skin
WO2013020719A2 (fr) Nouvelle utilisation de compositions pour retarder l'initiation de la phase catagène des cheveux
ITUB20159582A1 (it) Composizione, per uso topico, utile per la prevenzione di disturbi di tipo infiammatorio e/o infettivo delle mucose.
CN112022868A (zh) 龙胆苦苷的防脱发和生发用途
US10071052B2 (en) Method for the prevention and treatment of acne
WO2019175902A1 (fr) Préparation topique pour diverses affections cutanées
Munro Diseases of the skin. Treatment of scalp disorders.
Kumar et al. A Review on Acne Vulgaris is an usual Dermatological Disorders which bothers People in their Adolescence
RU2705162C1 (ru) Мазь для лечения псориаза (варианты)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12713980

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12713980

Country of ref document: EP

Kind code of ref document: A2